Keyword Analysis & Research: jasper therapeutics

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
jasper therapeutics1.680.2480419
jasper0.070.82344996
therapeutics0.760.759138312

Keyword Research: People who searched jasper therapeutics also searched

Keyword CPC PCC Volume Score
jasper therapeutics1.141886851
jasper therapeutics stock0.980.7502939
jasper therapeutics website0.70.5836077
jasper therapeutics stock price0.240.941753
jasper therapeutics news0.290.1702212
jasper therapeutics pipeline0.1177025
jasper therapeutics logo0.2818871
jasper therapeutics google0.130.4748113
jasper therapeutics spac0.190.693711
jasper therapeutics cnbc1.330.7781660
jasper therapeutics ticker0.420.597179
jasper therapeutics funding1.511180324
jasper therapeutics location1.19169855
jasper therapeutics linkedin0.780.5663760
jasper therapeutics inc0.220.6356383
jasper therapeutics share price0.50.9845255
jasper therapeutics email format0.730.46585
jasper therapeutics market cap1.910.411233
what is jasper therapeutics trading at now0.750.995219

Search Results related to jasper therapeutics on Search Engine

  • Home - Jasper Therapeutics

    jaspertherapeutics.com

    https://www.jaspertherapeutics.com/

    WebJasper is a biotechnology company focused on targeting mast cells and stem cells to treat chronic diseases. Our mission is to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to ...

    DA: 39 PA: 13 MOZ Rank: 25

  • Jasper Therapeutics, Inc. (JSPR) - Yahoo Finance

    yahoo.com

    https://finance.yahoo.com/quote/JSPR/

    WebJasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.

    DA: 22 PA: 12 MOZ Rank: 41

  • Pipeline - Jasper Therapeutics

    jaspertherapeutics.com

    https://www.jaspertherapeutics.com/pipeline/

    WebJasper is a clinical stage biotechnology company focused on the development of novel curative therapies by focusing on the biology of the hematopoietic stem cell. Jasper’s lead program, Briquilimab, is an investigational therapy currently being studied in multiple clinical trials for serious and life-threatening conditions.

    DA: 34 PA: 55 MOZ Rank: 8

  • About Us - Jasper Therapeutics

    jaspertherapeutics.com

    https://www.jaspertherapeutics.com/about-us/

    WebAbout Jasper. Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare ...

    DA: 46 PA: 52 MOZ Rank: 62

  • News Releases | Jasper Therapeutics, Inc

    jaspertherapeutics.com

    https://ir.jaspertherapeutics.com/news-events/news-releases

    WebFeb 26, 2024 · REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria.

    DA: 35 PA: 28 MOZ Rank: 78

  • Investor Relations | Jasper Therapeutics, Inc

    jaspertherapeutics.com

    https://ir.jaspertherapeutics.com/

    WebApr 2, 2024 · Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA ...

    DA: 82 PA: 73 MOZ Rank: 38

  • Jasper Therapeutics Announces First Patient Dosed in Phase …

    jaspertherapeutics.com

    https://ir.jaspertherapeutics.com/news-releases/news-release-details/jasper-therapeutics-announces-first-patient-dosed-phase-1b2a

    WebMarch 19, 2024. PDF Version. REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and …

    DA: 38 PA: 82 MOZ Rank: 99

  • Science - Jasper Therapeutics

    jaspertherapeutics.com

    https://www.jaspertherapeutics.com/science/

    WebScientific Approach. At Jasper, we are dedicated to bringing cures for patients suffering from mast and hematopoietic stem cell diseases. In mast cell diseases our approach is to directly target and deplete the cells that are responsible for …

    DA: 68 PA: 10 MOZ Rank: 74

  • Jasper Therapeutics Presents Positive Final Results from Phase …

    jaspertherapeutics.com

    https://ir.jaspertherapeutics.com/news-releases/news-release-details/jasper-therapeutics-presents-positive-final-results-phase-1

    WebDec 10, 2023 · Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023 | Jasper Therapeutics, Inc.

    DA: 52 PA: 32 MOZ Rank: 1

  • Jasper Therapeutics Announces First Patient Dosed in a Phase 1 …

    jaspertherapeutics.com

    https://ir.jaspertherapeutics.com/news-releases/news-release-details/jasper-therapeutics-announces-first-patient-dosed-phase-1-trial

    WebREDWOOD CITY, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (LR …

    DA: 88 PA: 52 MOZ Rank: 80